The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Peritoneal Carcinomatosis of Unknown Primary Site in Women: A Distinctive Subset of Adenocarcinoma

Charles M. Strnad, MD; William W. Grosh, MD; Jere Baxter, MD; Lonnie S. Burnett, MD; Howard W. Jones III, MD; F. Anthony Greco, MD; and John D. Hainsworth, MD
[+] Article, Author, and Disclosure Information

Requests for Reprints: John D. Hainsworth, MD, Division of Oncology, 1956 The Vanderbilt Clinic, Nashville, TN 37232.

Current Author Addresses: Dr. Strnad: 6835 S. Canton, Tulsa, OK 74136.

Dr. Grosh: Primary Care Center, Box 465, University of Virginia, Charlottesville, VA 22908.

Dr. Baxter: Department of Pathology, Nashville Memorial Hospital, 612 West Due West, Madison, TN 37115.

Drs. Burnett and Jones: Department of Obstetrics/Gynecology, T-2302 Vanderbilt Medical Center North, Nashville, TN 37232. Drs. Greco and Hainsworth: Division of Oncology, 1956 The Vanderbilt Clinic, Nashville, TN 37232.

© 1989 American College of PhysiciansAmerican College of Physicians

Ann Intern Med. 1989;111(3):213-217. doi:10.7326/0003-4819-111-3-213
Text Size: A A A

Study Objective: To define the clinical features and results of systemic treatment in women with adenocarcinoma of unknown primary site involving predominantly the peritoneal surfaces.

Design: Retrospective analysis of 18 patients treated at a single institution between 1978 and 1984.

Patients: All 18 women had abdominal carcinomatosis and had no primary site identified at laparotomy. Nine patients had limited residual tumor (maximal tumor diameter, 3 cm or less) after initial cytoreductive surgery, and 9 patients had extensive residual disease.

Interventions: In general, patients were treated according to standard guidelines for treatment of advanced ovarian carcinoma. All patients had initial laparotomy with attempted cytoreduction; of these 18 patients, 16 subsequently received cisplatin-based chemotherapy. Patients were restaged either clinically (10 patients) or with second-look surgery (8 patients).

Results: The median survival for all patients was 23 months. Five patients had complete response to chemotherapy, and three patients remain disease-free 41, 59, and 77 months after diagnosis. Patients with limited residual disease had longer median survival than did those with extensive residual disease (31 months compared with 11 months).

Conclusions: Women with adenocarcinoma of unknown primary site involving predominantly the peritoneal surface should be distinguished from other patients with adenocarcinoma of unknown primary site because they have a more indolent disease course, a higher response rate to systemic therapy, and a chance for long-term, disease-free survival after therapy. Although optimal treatment is undefined, we recommend that these patients be treated using the guidelines established for therapy of advanced ovarian carcinoma, including initial surgical cytoreduction followed by cisplatin-based combination chemotherapy.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $42.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.